Clinic
Methodist Health Centers
Methodist Health Centers was paid $17.33M by Medicaid between Jan 2020 and Nov 2024, across 84 billing codes. Its largest line is 99284, emergency room visit (serious) — 73% of everything it billed.
33Billing provider infoMETHODIST HEALTH CENTERS
HOUSTON, TX 77070
HOUSTON, TX 77070
33aNPI1871619254assigned 03/21/2007
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$17.33M
24GClaims135,016
24DCodes billed84
24AFirst – last monthJan 2020 – Nov 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#28 of 320
Median peer was paid$205K
This provider vs. median85×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 959 | $202K | |
| 2021 | 32,663 | $3.88M | |
| 2022 | 44,189 | $5.40M | |
| 2023 | 38,686 | $5.84M | |
| 2024incomplete | 18,519 | $2.01M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 73% | 14,015 | 13,456 | $12.56M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 11,608 | 11,164 | $1.76M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.9% | 2,571 | 2,432 | $1.20M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 2,771 | 2,681 | $366K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 2,950 | 2,693 | $232K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 4,411 | 4,254 | $198K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,802 | 5,541 | $144K |
| 80053 | Comprehensive metabolic panel | <1% | 13,200 | 11,784 | $109K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 15,609 | 13,594 | $80K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,679 | 5,468 | $78K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 486 | 472 | $77K |
| 76801 | <1% | 775 | 676 | $71K |
72 more codes
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,272 | $64K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 633 | $49K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 850 | $42K |
| G0378 | Hospital observation service, per hour | <1% | 476 | $23K |
| 87400 | <1% | 2,003 | $22K | |
| 84703 | <1% | 3,649 | $20K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 844 | $20K |
| 81001 | <1% | 5,715 | $17K | |
| 84484 | <1% | 3,716 | $17K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 207 | $14K |
| 87088 | <1% | 2,410 | $13K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 907 | $12K |
| 86850 | <1% | 817 | $12K | |
| 83880 | <1% | 1,117 | $11K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 357 | $11K |
| 84702 | <1% | 1,019 | $10K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 339 | $9K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 114 | $8K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 959 | $7K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 360 | $6K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,566 | $6K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,635 | $5K |
| 83690 | <1% | 1,291 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,188 | $4K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 496 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 159 | $3K |
| 87070 | <1% | 295 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 539 | $2K |
| 81003 | <1% | 961 | $2K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 30 | $2K |
| 83735 | <1% | 1,518 | $2K | |
| 86901 | <1% | 1,089 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,323 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 38 | $2K |
| 86900 | <1% | 934 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 465 | $1K |
| 85610 | <1% | 1,146 | $1K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 15 | $1K |
| 74018 | <1% | 25 | $1K | |
| 85730 | <1% | 645 | $1K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 962 | $1K |
| 87077 | <1% | 358 | $993.66 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 175 | $887.46 |
| 83605 | <1% | 208 | $865.78 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 805 | $710.97 |
| 87186 | <1% | 219 | $651.93 | |
| CP007 | <1% | 13 | $589.91 | |
| 87420 | <1% | 37 | $572.84 | |
| 85027 | <1% | 180 | $521.86 | |
| 86769 | <1% | 32 | $427.20 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 162 | $385.09 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 76 | $380.14 |
| 87040 | <1% | 60 | $326.53 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,063 | $316.31 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 938 | $278.29 |
| 84100 | <1% | 560 | $268.37 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 12 | $228.92 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 244 | $209.47 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 157 | $204.69 |
| 82247 | <1% | 12 | $173.80 | |
| 87210 | <1% | 22 | $132.05 | |
| 80061 | Lipid panel | <1% | 69 | $105.88 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 28 | $97.66 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 42 | $65.05 |
| 97161 | <1% | 12 | $22.14 | |
| 82570 | <1% | 16 | $8.70 | |
| 96376 | <1% | 122 | $8.44 | |
| 84156 | <1% | 16 | $6.16 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 14 | $5.34 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 45 | $3.48 |
| J2704 | Injection, propofol, 10 mg | <1% | 321 | $0.28 |
| 80197 | 0% | 37 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBARBER, KEITH (CEO)